BeyondSpring Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $29.6M
- Price
- $0.7201
- % Change (Daily % change from the live per-ticker quote feed.)
- 0.00%
- Volume
- 59.4K
About
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
Quick stats
Shares outstanding41.1M
Computed float29.7M
Float / shares72.2%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001677940
AI Summary
AI-generated1/8
standardmixedearnings
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update
BeyondSpring reported updated Phase 2 data for Plinabulin in combination with docetaxel and pembrolizumab, demonstrating a 58% two-year overall survival rate in metastatic NSCLC patients who progressed on first-line ICI therapy.
The company completed a leadership transition effective July 1, 2026, appointing Min Qiu as CEO and Na Li as CFO to prioritize the DUBLIN-4 confirmatory program and financing efforts.
Q2 2026 financial results reported a net loss of $1.8 million with R&D expenses at $1.0 million, while cash and short-term investments declined to $6.5 million from $12.6 million at the end of 2025.
Red flags
- Cash, cash equivalents, and short-term investments dropped from $12.6 million at year-end 2025 to $6.5 million as of June 30, 2026.
- Company is pre-revenue with a limited cash runway.